Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection

Therapeutic Advances in Infectious Disease

Volumn 3, Issue 1, 2016, Pages 23-42

  Spigaglia, Patrizia ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Clostridium difficile; antimicrobial susceptibility; clindamycin; fluoroquinolones; metronidazole; mobile genetic elements; multidrug resistance; rifamycins

Indexed keywords

BETA LACTAMASE; CARBONYL CYANIDE CHLOROPHENYLHYDRAZONE; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING); ERYTHROMYCIN; FIDAXOMICIN; GATIFLOXACIN; LINCOSAMIDE; MACROLIDE; METRONIDAZOLE; MIKAMYCIN B; MOXIFLOXACIN; PENICILLIN BINDING PROTEIN; PEPTIDOGLYCAN GLYCOSYLTRANSFERASE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIBOSOME PROTEIN; RIFAMYCIN; RNA POLYMERASE; TETRACYCLINE; VANCOMYCIN;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATE; CLOSTRIDIUM DIFFICILE INFECTION; DISK DIFFUSION; GENE EXPRESSION; GENE MUTATION; HOMOLOGOUS RECOMBINATION; INFECTION CONTROL; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MULTILOCUS SEQUENCE TYPING; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; REVIEW; TANDEM REPEAT;

EID: 84964493540     PISSN: 20499361     EISSN: 2049937X     Source Type: Journal    
DOI: 10.1177/2049936115622891     Document Type: Review

References (171)

1. G.AckermannY.TangR.KueperP.HeisigA.RodloffJ.Silva (2001) Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyr A. Antimicrob Agents Chemother45: 2348–2353.
2. G.AckermannY.Tang-FeldmanR.SchaumannJ.HendersonA.RodloffJ.Silva (2003) Antecedent use of fluoroquinolones is associated with resistance to moxifloxacin in Clostridium difficile. Clin Microbiol Infect9: 526–530.
3. A.AdlerT.Miller-RollR.BradensteinC.BlockB.MendelsonM.Parizade (2015) A national survey of the molecular epidemiology of Clostridium difficile in Israel: the dissemination of the ribotype 027 strain with reduced susceptibility to vancomycin and metronidazole. Diagn Microbiol Infect Dis83: 21–24.
4. S.Álvarez-PérezJ.BlancoE.Martínez-NevadoT.PeláezC.HarmanusE.Kuijper (2014) Shedding of Clostridium difficile PCR ribotype 078 by zoo animals, and report of an unstable metronidazole-resistant isolate from a zebra foal (Equus quagga burchellii). Vet Microbiol169: 218–222.
5. N.AmbroseM.JohnsonD.BurdonM.Keighley (1985) The influence of single dose intravenous antibiotics on faecal flora and emergence of Clostridium difficile. J Antimicrob Chemother15: 319–326.
6. F.AmmamJ.MarvaudT.Lambert (2012) Distribution of the vanG-like gene cluster in Clostridium difficile clinical isolates. Can J Microbiol58: 547–551.
7. F.AmmamD.Meziane-CherifD.Mengin-LecreulxD.BlanotD.PatinI.Boneca (2013) The functional vanGCd cluster of Clostridium difficile does not confer vancomycin resistance. Mol Microbiol89: 612–625.
8. S.BainesR.O’ConnorJ.FreemanW.FawleyC.HarmanusP.Mastrantonio (2008) Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother62: 1046–1052.
9. R.BaldanA.TrovatoV.BianchiniA.BiancardiP.CicheroM.Mazzotti (2015) A successful epidemic genotype: Clostridium difficile PCR ribotype 018. J Clin Microbiol53: 2575–2580.
10. J.BartlettA.OnderdonkR.CisnerosD.Kasper (1977) Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis136: 701–705.
11. M.BauerD.NotermansB.van BenthemJ.BrazierM.WilcoxM.Rupnik (2011) Clostridium difficile infection in Europe: a hospital-based survey. Lancet377: 63–73.
12. G.Bignardi (1998) Risk factors for Clostridium difficile infection. J Hosp Infect40: 1–15.
13. R.BoltonM.Culshaw (1986) Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut27: 1169–1172.
14. J.BrazierW.FawleyJ.FreemanM.Wilcox (2001) Reduced susceptibility of Clostridium difficile to metronidazole. J Antimicrob Chemother48: 741–742.
15. M.BrouwerP.WarburtonA.RobertsP.MullanyE.Allan (2011) Genetic organisation, mobility and predicted functions of genes on integrated, mobile genetic elements in sequenced strains of Clostridium difficile. PLoS One6: e23014.
16. M.BrouwerA.RobertsP.MullanyE.Allan (2012) In silico analysis of sequenced strains of Clostridium difficile reveals a related set of conjugative transposons carrying a variety of accessory genes. Mob Genet Elements2: 8–12.
17. A.BüchlerS.RampiniS.StellingB.LedergerberS.PeterA.Schweiger (2014) Antibiotic susceptibility of Clostridium difficile is similar worldwide over two decades despite widespread use of broad-spectrum antibiotics: an analysis done at the University Hospital of Zurich. BMC Infect Dis14: 607.
18. F.BurckhardtA.FriedrichD.BeierT.Eckmanns (2008) Clostridium difficile surveillance trends, Saxony, Germany. Emerg Infect Dis4: 691–692.
19. R.CarmanC.GenheimerF.RafiiM.ParkM.HiltonsmithD.Lyerly (2009) Diversity of moxifloxacin resistance during a nosocomial outbreak of a predominantly ribotype ARU 027 Clostridium difficile diarrhea. Anaerobe15: 244–248.
20. R.CarmanJ.BooneH.GroverK.WickhamL.Chen (2012) In vivo selection of rifamycin-resistant Clostridium difficile during rifaximin therapy. Antimicrob Agents Chemother56: 6019–6020.
21. S.CartmanJ.HeapS.KuehneA.CockayneN.Minton (2010) The emergence of “hypervirulence” in Clostridium difficile. Inter J Med Microbiol300: 387–395.
22. F.Chaparro-RojasK.Mullane (2013) Emerging therapies for Clostridium difficile infection – focus on fidaxomicin. Infect Drug Resist6: 41–53.
23. J.ChiaH.LaiL.SuA.KuoT.Wu (2013) Molecular epidemiology of Clostridium difficile at a medical center in Taiwan: persistence of genetically clustering of A−B+ isolates and increase of A+B+ isolates. PLoS One8: e75471.
24. P.ChongT.LynchS.McCorristerP.KibseyM.MillerD.Gravel (2014) Proteomic analysis of a NAP1 Clostridium difficile clinical isolate resistant to metronidazole. PLoS One9: e82622.
25. A.ClementsR.MagalhãesA.TatemD.PatersonT.Riley (2010) Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Infect Dis10: 395–404.
26. Clinical and Laboratory Standards Institute (2012) Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard-Eighth Edition. CLSI document M11-A8
27. Clinical and Laboratory Standards Institute (2015) Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement. CLSI document M100-S25
28. J.CorverD.BakkerM.BrouwerC.HarmanusM.HensgensA.Roberts (2012) Analysis of a Clostridium difficile PCR ribotype 078 100 kilobase island reveals the presence of a novel transposon, Tn6164. BMC Microbiol12: 130.
29. S.CurryJ.MarshK.ShuttC.MutoM.O’LearyM.Saul (2009) High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis48: 425–429.
30. T.DapaR.LeuzziY.NgS.BabanR.AdamoS.Kuehne (2013) Multiple factors modulate biofilm formation by the anaerobic pathogen Clostridium difficile. J Bacteriol195: 545–555.
31. F.de LallaG.PriviteraG.OrtisiG.RizzardiniD.SantoroA.Pagano (1989) Third generation cephalosporins as a risk factor for Clostridium difficile-associated disease: a four-year survey in a general hospital. J Antimicrob Chemother23: 623–631.
32. S.DebastM.BauerE.Kuijper (2014) European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect20: 1–26.
33. K.DingleB.ElliottE.RobinsonD.GriffithsD.EyreN.Stoesser (2014) Evolutionary history of the Clostridium difficile pathogenicity locus. Genome Biol Evol6: 36–52.
34. D.DongL.ZhangX.ChenC.JiangB.YuX.WangY.Peng (2013) Antimicrobial susceptibility and resistance mechanisms of clinical Clostridium difficile from a Chinese tertiary hospital. Int J Antimicrob Agents41: 80–84.
35. D.DongX.ChenC.JiangL.ZhangG.CaiL.Han (2014) Genetic analysis of Tn916-like elements conferring tetracycline resistance in clinical isolates of Clostridium difficile. Int J Antimicrob Agents43: 73–77.
36. L.DridiJ.TankovicB.BurghofferF.BarbutJ.Petit (2002) Gyr A and gyrB mutations are implicated in cross-resistance to ciprofloxacin and moxifloxacin in Clostridium difficile. Antimicrob Agents Chemother46: 3418–3421.
37. D.DrudyT.QuinnR.O’MahonyL.KyneP.O’GaoraS.Fanning (2006) High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile. J Antimicrob Chemother58: 1264–1267.
38. D.DrudyL.KyneR.O’MahonyS.Fanning (2007) gyrA mutations in fluoroquinolone-resistant Clostridium difficile PCR-027. Emerg Infect Dis13: 504–505.
39. E.DubberkeM.Olsen (2012) Burden of Clostridium difficile on the healthcare system. Clin Infect Dis55(Suppl. 2): S88–S92.
40. C.EckertB.CoignardM.HebertC.TarnaudC.TessierA.Lemire (2013) Clinical and microbiological features of Clostridium difficile infections in France: The ICD-RAISIN 2009 national survey. Méd Mal Infect43: 67–74.
41. Z.EitelG.TerhesJ.SókiE.NagyE.Urbán (2015) Investigation of the MICs of fidaxomicin and other antibiotics against Hungarian Clostridium difficile isolates. Anaerobe31: 47–49.
42. M.FalagasG.MakrisG.DimopoulosD.Matthaiou (2008) Heteroresistance: a concern of increasing clinical significance?Clin Microbiol Infect14: 101–104.
43. K.FarrowD.LyrasJ.Rood (2001) Genomic analysis of the erythromycin resistance element Tn5398 from Clostridium difficile. Microbiology147: 2717–2728.
44. J.FreemanJ.StottS.BainesW.FawleyM.Wilcox (2005) Surveillance for resistance to metronidazole and vancomycin in genotypically distinct and UK epidemic Clostridium difficile isolates in a large teaching hospital. J Antimicrob Chemother56: 988–989.
45. J.FreemanM.BauerS.BainesJ.CorverW.FawleyB.Goorhuis (2010) The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev23: 529–549.
46. J.FreemanJ.VernonK.MorrisS.NicholsonS.TodhunterC.Longshaw (2015) Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes. Clin Microbiol Infect21: 248.e9–248.e16.
47. P.FryS.ThakurM.AbleyW.Gebreyes (2012) Antimicrobial resistance, toxinotype, and genotypic profiling of Clostridium difficile isolates of swine origin. J Clin Microbiol50: 2366–2372.
48. M.GalJ.Brazier (2004) Metronidazole resistance in Bacteroides spp. carrying nim genes and the selection of slow-growing metronidazole-resistant mutants. J Antimicrob Chemother54: 109–116.
49. D.Gerding (2004) Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile–associated diarrhea: this is an antimicrobial resistance problem. Clin Infect Dis38: 646–648.
50. S.GohH.HussainB.ChangW.EmmettT.RileyP.Mullany (2013) Phage φC2 mediates transduction of Tn6215, encoding erythromycin resistance, between Clostridium difficile strains. MBio4: e00840–e00813.
51. P.Goldman (1982) The development of 5-nitroimidazoles for the treatment and prophylaxis of anaerobic bacterial infections. J Antimicrob Chemother10(Suppl. A): 23–33.
52. A.GoorhuisT.Van der KooiN.VaessenF.DekkerR.Van den BergC.Harmanus (2007) Spread and epidemiology of Clostridium difficile polymerase chain reaction ribotype 027/toxinotype III in The Netherlands. Clin Infect Dis45: 695–703.
53. A.GoorhuisS.DebastL.van LeengoedC.HarmanusD.NotermansA.Bergwerff (2008) Clostridium difficile PCR ribotype 078: an emerging strain in humans and in pigs?J Clin Microbiol46: 1157–1158.
54. E.GoldsteinD.CitronP.SearsF.BabakhaniS.SambolD.N.Gerding (2011) Comparative susceptibilities of fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two fidaxomicin phase III trials of C. difficile infection. Antimicrob Agents Chemother55: 5194–5199.
55. E.GoldsteinF.BabakhaniD.Citron (2012) Antimicrobial activities of fidaxomicin. Clin Infect Dis55(Suppl. 2): S143–S148.
56. M.GoudarziH.GoudarziM.AlebouyehM.Azimi RadF.Shayegan MehrM.Zali (2013) Antimicrobial susceptibility of Clostridium difficile clinical isolates in Iran. Iran Red Crescent Med J15: 704–711.
57. D.GravelM.MillerA.SimorG.TaylorM.GardamA.McGeer (2009) Canadian Nosocomial Infection Surveillance Program. Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program study. Clin Infect Dis48: 568–576.
58. H.HächlerB.Berger-BächiF.Kayser (1987) Genetic characterization of a Clostridium difficile erythromycin-clindamycin resistance determinant that is transferable to Staphylococcus aureus. Antimicrobial Agents Chemother7: 1039–1045.
59. M.HeM.SebaihiaT.LawleyR.StablerL.DawsonM.Martin (2010) Evolutionary dynamics of Clostridium difficile over short and long time scales. Proc Natl Acad Sci USA107: 7527–7532.
60. M.HeF.MiyajimaP.RobertsL.EllisonD.PickardM.Martin (2013) Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet45: 109–113.
61. H.HuangA.WeintraubH.FangC.Nord (2009) Antimicrobial resistance in Clostridium difficile. Int J Antimicrob Agents34: 516–522.
62. J.HuangZ.JiangK.GareyT.LascoH.Dupont (2013) Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile. Antimicrob Agents Chemother57: 2690–2693.
63. M.ImpallomeniN.GalletlyJ.WortJ.StarrT.Rogers (1995) Increased risk of diarrhoea caused by Clostridium difficile in elderly patients receiving cefotaxime. BMJ311: 1345–1346.
64. A.JarradT.KaroliM.BlaskovichD.LyrasM.Cooper (2015) Clostridium difficile drug pipeline: challenges in discovery and development of new agents. J Med Chem58: 5164–5185.
65. A.JasniP.MullanyH.HussainA.Roberts (2010) Demonstration of conjugative transposon (Tn5397)-mediated horizontal gene transfer between Clostridium difficile and Enterococcus faecalis. Antimicrob Agents Chemother54: 4924–4926.
66. S.JohnsonM.SamoreK.FarrowG.KillgoreF.TenoverD.Lyras (1999) Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med341: 1645–1651.
67. S.JohnsonC.SchrieverU.PatelT.PatelD.HechtD.Gerding (2009) Rifaximin redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. Anaerobe15: 290–291.
68. J.KarlowskyG.ZhanelG.HammondE.RubinsteinJ.WylieT.Du (2012) Multidrug-resistant North American pulsotype 2 Clostridium difficile was the predominant toxigenic hospital-acquired strain in the province of Manitoba, Canada, in 2006–2007. J Med Microbiol61: 693–700.
69. K.KeeJ.BrazierK.PostS.WeeseJ.Songer (2007) Prevalence of PCR ribotypes among Clostridium difficile isolates from pigs, calves, and other species. J Clin Microbiol45: 1963–1964.
70. R.KhanJ.Cheesbrough (2003) Impact of changes in antibiotic policy on Clostridium difficile-associated diarrhoea (CDAD) over a five-year period in a district general hospital. J Hosp Infect54: 104–108.
71. J.KimS.SmathersP.PrasadK.LeckermanS.CoffinT.Zaoutis (2008) Epidemiological features of Clostridium difficile-associated disease among inpatients at children’s hospitals in the United States, 2001–2006. Pediatrics122: 1266–1270.
72. J.KimJ.KangH.PaiT.Choi (2012) Association between PCR ribotypes and antimicrobial susceptibility among Clostridium difficile isolates from healthcare-associated infections in South Korea. Int J Antimicrob Agents40: 24–29.
73. D.KnightS.GiglioP.HuntingtonT.KormanD.KotsanasC.Moore (2015) Surveillance for antimicrobial resistance in Australian isolates of Clostridium difficile, 2013–14. J Antimicrob Chemother70: 2992–2999.
74. Krutova, M., Matejkova, J., Tkadlec, J. and Nyc, O. (2015) Antibiotic profiling of Clostridium difficile ribotype 176 - A multidrug resistant relative to C. difficile ribotype 027. Anaerobe. DOI: 10.1016/j.anaerobe.2015.07.009
75. Y.KuwataS.TanimotoE.SawabeM.ShimaY.TakahashiH.Ushizawa (2015) Molecular epidemiology and antimicrobial susceptibility of Clostridium difficile isolated from a university teaching hospital in Japan. Eur J Clin Microbiol Infect34: 763–772.
76. D.LachowiczH.PituchP.Obuch-Woszczatyński (2015) Antimicrobial susceptibility patterns of Clostridium difficile strains belonging to different polymerase chain reaction ribotypes isolated in Poland in 2012. Anaerobe31: 37–41.
77. J.LeeY.LeeK.LeeT.RileyH.Kim (2014) The changes of PCR ribotype and antimicrobial resistance of Clostridium difficile in a tertiary care hospital over 10 years. J Med Microbiol63: 819–823.
78. J.LeedsM.SachdevaS.MullinS.BarnesA.Ruzin (2014) In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin. J Antimicrob Chemother69: 41–44.
79. F.LessaC.GouldL.McDonald (2012) Current status of Clostridium difficile infection epidemiology. Clin Infect Dis55: 65–70.
80. F.LessaY.MuW.BambergZ.BeldavsG.DumyatiJ.Dunn (2015) Burden of Clostridium difficile Infection in the United States. N Engl J Med372: 825–834.
81. C.LiaoW.KoJ.LuP.Hsueh (2012) Characterizations of clinical isolates of Clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan. Antimicrob Agents Chemother56: 3943–3949.
82. B.LimbagoC.LongA.ThompsonG.KillgoreG.HannettN.Havill (2009) Clostridium difficile strains from community-associated infections. J Clin Microbiol47: 3004–3007.
83. T.LouieM.MillerK.MullaneK.WeissA.LentnekY.Golan (2011) Fidaxomicin versus Vancomycin for Clostridium difficile Infection. N Engl J Med364: 422–431.
84. T.LouieK.CannonB.ByrneJ.EmeryL.WardM.Eyben (2012) Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis55(Suppl. 2): S132–S142.
85. T.LynchP.ChongJ.ZhangR.HizonT.DuM.Graham (2013) Characterization of a stable, metronidazole-resistant Clostridium difficile clinical isolate. PLoS One8: e53757.
86. D.LyrasC.StorieA.HugginsP.CrellinT.BannamJ.Rood (1998) Chloramphenicol resistance in Clostridium difficile is encoded on Tn4453 transposons that are closely related to Tn4451 from Clostridium perfringens. Antimicrob Agents Chemother42: 1563–1567.
87. D.LyrasM.Cooper (2015) Clostridium difficile drug pipeline: challenges in discovery and development of new agents. J Med Chem58: 5164–5185.
88. Mac Aogáin, M., Kilkenny, S., Walsh, C., Lindsay, S., Moloney, G., Morris, T. et al. (2015) Identification of a novel mutation at the primary dimer interface of GyrA conferring fluoroquinolone resistance in Clostridium difficile. JGAR, in press. DOI: 10.1016/j.jgar.2015.09.007
89. L.McDonaldG.KillgoreA.ThompsonR.OwensS.KazakovaS.Sambol (2005) An epidemic, toxin gene–variant strain of Clostridium difficile. N Engl J Med353: 2433–2441.
90. B.MillerL.ChenD.SextonD.Anderson (2011) Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol32: 387–390.
91. M.MillerR.BlanchetteP.SpigagliaF.BarbantiP.Mastrantonio (2011) Divergent rifamycin susceptibilities of Clostridium difficile strains in Canada and Italy and predictive accuracy of rifampin Etest for rifamycin resistance. J Clin Microbiol49: 4319–4321.
92. I.MouraP.SpigagliaF.BarbantiP.Mastrantonio (2013) Analysis of metronidazole susceptibility in different Clostridium difficile PCR ribotypes. J Antimicrob Chemother68: 362–365.
93. I.MouraM.MonotC.TaniP.SpigagliaF.BarbantiN.Norais (2014) Multidisciplinary analysis of a nontoxigenic Clostridium difficile strain with stable resistance to metronidazole. Antimicrob Agents Chemother58: 4957–4960.
94. K.MullaneS.Gorbach (2011) Fidaxomicin: first-in-class macrocyclic antibiotic. Expert Rev Anti Infect Ther9: 767–777.
95. P.MullanyM.WilksI.LambC.ClaytonB.WrenS.Tabaqchali (1990) Genetic analysis of a tetracycline resistance determinant from Clostridium difficile and its conjugal transfer to and from Bacillus subtilis. J Gen Microbiol136: 1343–1349.
96. P.MullanyM.WilksS.Tabaqchali (1995) Transfer of macrolide-lincosamide-streptogramin B (MLS) resistance in Clostridium difficile is linked to a gene homologous with toxin A and is mediated by a conjugative transposon, Tn5398. J Antimicrob Chemother2: 305–315.
97. P.MullanyR.WilliamsG.LangridgeD.TurnerR.WhalanC.Clayton (2012) Behavior and target site selection of conjugative transposon Tn916 in two different strains of toxigenic Clostridium difficile. Appl Environ Microbiol78: 2147–2153.
98. P.MullanyE.AllanA.Roberts (2015) Mobile genetic elements in Clostridium difficile and their role in genome function. Res Microbiol166: 361–367.
99. D.MusherS.AslamN.LoganS.NallacheruI.BhailaF.Borchert (2005) Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis40: 1586–1590.
100. C.MutoM.PokrywkaK.ShuttA.MendelsohnK.NouriK.Posey (2005) A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol26: 273–280.
101. C.MutoM.BlankJ.MarshE.VergisM.O'LearyK.Shutt (2007) Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive “bundle” approach. Clin Infect Dis45: 1266–1273.
102. K.NormanH.ScottR.HarveyB.NorbyM.Hume (2014) Comparison of antimicrobial susceptibility among Clostridium difficile isolated from an integrated human and swine population in Texas. Foodborne Pathog Dis11: 257–264.
103. A.NovakP.SpigagliaF.BarbantiI.Goic-BarisicM.Tonkic (2014) First clinical and microbiological characterization of Clostridium difficile infection in a Croatian University Hospital. Anaerobe30: 18–23.
104. J.O’ConnorM.GalangS.SambolD.HechtG.VedantamD.Gerding (2008) Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother52: 2813–2817.
105. P.Obuch-WoszczatyńskiG.DubielC.HarmanusE.KuijperU.DudaD.Wultańska (2013) Emergence of Clostridium difficile infection in tuberculosis patients due to a highly rifampicin-resistant PCR ribotype 046 clone in Poland. Eur J Clin Microbiol Infect Dis32: 1027–103.
106. P.Obuch-WoszczatyńskiD.LachowiczA.SchneiderA.MólJ.PawłowskaE.Ożdżeńska-Milke (2014) Occurrence of Clostridium difficile PCR-ribotype 027 and it’s closely related PCR-ribotype 176 in hospitals in Poland in 2008–2010. Anaerobe28: 13–17.
107. K.OkaT.OsakiT.HanawaS.KurataM.OkazakiT.Manzoku (2012) Molecular and microbiological characterization of Clostridium difficile isolates from single, relapse, and reinfection cases. J Clin Microbiol50: 915–921.
108. E.OldfieldIVE.OldfieldIIID.Johnson (2014) Clinical update for the diagnosis and treatment of Clostridium difficile infection. World J Gastrointest Pharmacol Ther5: 1–26.
109. Optimer Pharmaceuticals, Inc. (2011) Anti-Infective Drugs Advisory Committee Briefing Document: Dificid™ (fidaxomicin tablets) for the treatment of Clostridium difficile infection (CDI), also known as Clostridium difficile-associated diarrhea (CDAD), and for reducing the risk of recurrence when used for treatment of initial CDI. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM249354.pdf (accessed 5 December 2015)
110. V.PecavarM.BlaschitzP.HufnaglJ.ZeinzingerA.FiedlerF.Allerberger (2012) High-resolution melting analysis of the single nucleotide polymorphism hot-spot region in the rpoB gene as an indicator of reduced susceptibility to rifaximin in Clostridium difficile. J Med Microbiol61: 780–785.
111. T.PeláezE.CercenadoL.AlcaláM.MarínA.Martín-LópezJ.Martínez-Alarcón (2008) Metronidazole resistance in Clostridium difficile is heterogeneous. J Clin Microbiol46: 3028–3032.
112. T.PeláezL.AlcaláJ.BlancoS.Álvarez-PérezM.MarínA.Martín-López (2013) Characterization of swine isolates of Clostridium difficile in Spain: A potential source of epidemic multidrug resistant strains?Anaerobe22: 45–49.
113. J.PépinM.ValiquetteM.AlaryP.VillemureA.PelletierK.Forget (2004) Clostridium difficile-associated diarrhea in a region of Quebec from 1991–2003: a changing pattern disease severity. CMAJ17: 466–472.
114. J.PépinM.AlaryL.ValiquetteE.RaicheJ.RuelK.Fulop (2005a) Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis40: 1591–1597.
115. J.PépinM.ValiquetteB.Clossette (2005b) Mortality attributed to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ173: 1037–1042.
116. H.PerkinsM.Nieto (1974) The chemical basis for the action of the vancomycin group of antibiotics. Ann. N Y Acad Sci235: 348–363.
117. T.PiršJ.AvberšekI.ZdovcB.KrtA.AndlovicT.Lejko-Zupanc (2013) Antimicrobial susceptibility of animal and human isolates of Clostridium difficile by broth microdilution. J Med Microbiol62: 1478–1485.
118. H.PituchJ.BrazierP.Obuch-WoszczatynskiD.WultanskaF.Meisel-MikolajczykM.Luczak (2006) Prevalence and association of PCR ribotypes of Clostridium difficile isolated from symptomatic patients from Warsaw with macrolide-lincosamide-streptogramin B (MLSB) type resistance. J Med Microbiol55: 207–213.
119. H.Pituch (2009) Clostridium difficile is no longer just a nosocomial infection or an infection of adults. Int J Antimicrob Agents33(Suppl. 1): S42–S45.
120. L.RatnayakeJ.McEwenN.HendersonD.NathwaniG.PhillipsD.Brown (2011) Control of an outbreak of diarrhoea in a vascular surgery unit caused by a high-level clindamycin-resistant Clostridium difficile PCR ribotype 106. J Hosp Infect79: 242–247.
121. M.RedelingsF.SorvilloL.Mascola (2007) Increase in Clostridium difficile-related mortality rates, United States, 1999–2004. Emerg Infect Dis13: 1417–1419.
122. M.ReilM.HensgensE.KuijperT.JakobiakH.GruberM.Kist (2012) Seasonality of Clostridium difficile infections in Southern Germany. Epidemiol Infect140: 1787–1793.
123. C.RichardsonP.KimC.LeeA.BersenasJ.Weese (2015) Comparison of Clostridium difficile isolates from individuals with recurrent and single episode of infection. Anaerobe33: 105–108.
124. A.RobertsP.JohanesenD.LyrasP.MullanyJ.Rood (2001) Comparison of Tn5397 from Clostridium difficile, Tn916 from Enterococcus faecalis and the CW459tet(M) element from Clostridium perfringens shows that they have similar conjugation regions but different insertion and excision modules. Microbiology147: 1243–1251.
125. A.RobertsP.Mullany (2011) Tn916-like genetic elements: a diverse group of modular mobile elements conferring antibiotic resistance. FEMS Microbiol Rev35: 856–871.
126. M.RobertsL.McFarlandP.MullanyM.Mulligan (1994) Characterization of the genetic basis of antibiotic resistance in Clostridium difficile. J Antimicrob Chemother33: 419–429.
127. D.Rodríguez-PardoB.AlmiranteR.BartoloméV.PomarB.MirelisF.Navarro (2013) Epidemiology of Clostridium difficile infection and risk factors for unfavorable clinical outcomes: results of a hospital-based study in Barcelona, Spain. J Clin Microbiol51: 1465–1473.
128. M.RupnikA.WidmerO.ZimmermannC.EckertF.Barbut (2008) Clostridium difficile toxinotype V, ribotype 078, in animals and humans. J Clin Microbiol46: 2146.
129. Salix Pharmaceuticals, Ltd (2003) posting date. Salix receives FDA notification that rifaximin amendment considered a complete response. Salix Pharmaceuticals, Raleigh, NC, 10 December. Available at: http://www.businesswire.com/news/home/20031210005070/en/Salix-Receives-FDA-Notification-Rifamixin-Amendment-Considered (accessed 5 December 2015)
130. M.SamoreK.BettinP.DeGirolamiC.ClabotsD.GerdingA.Karchmer (1994) Wide diversity of Clostridium difficile types at a tertiary referral hospital. J Infect Dis170: 615–621.
131. M.SamoreG.KillgoreS.JohnsonR.GoodmanJ.ShimL.Venkataraman (1997) Multicenter typing comparison of sporadic and outbreak Clostridium difficile isolates from geographically diverse hospitals. J Infect Dis176: 1233–1238.
132. C.SchmidtB.LöfflerG.Ackermann (2007) Antimicrobial phenotypes and molecular basis in clinical strains of Clostridium difficile. Diagn Microbiol Infect Dis59: 1–5.
133. P.SearsD.CrookT.LouieM.MillerK.Weiss (2012) Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection. Clin Infect Dis55(Suppl. 2): S116–S120.
134. M.SebaihiaB.WrenP.MullanyN.FairweatherN.MintonR.Stabler (2006) The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome. Nat Genet38: 779–786.
135. M.SenohH.KatoT.FukudaA.NiikawaY.HoriH.Hagiya (2015) Predominance of PCR-ribotypes, 018 (smz) and 369 (trf) of Clostridium difficile in Japan: A potential relationship with other global circulating strains?J Med Microbiol64: 1226–1236.
136. C.SimangoS.Uladi (2014) Detection of Clostridium difficile diarrhoea in Harare, Zimbabwe. Trans R Soc Trop Med Hyg108: 354–357.
137. C.SlimingsT.Riley (2014) Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother69: 881–891.
138. P.SpigagliaF.BarbantiP.Mastrantonio (2006) New variants of the tet(M) gene in Clostridium difficile clinical isolates harbouring Tn916-like elements. J Antimicrob Chemother57: 1205–1209.
139. P.SpigagliaF.BarbantiP.Mastrantonio (2007) Detection of a genetic linkage between genes coding for resistance to tetracycline and erythromycin in Clostridium difficile. Microb Drug Resist13: 90–95.
140. P.SpigagliaF.BarbantiP.MastrantonioJ.BrazierF.BarbutM.Delmée (2008a) Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe. J Med Microbiol57: 784–789.
141. P.SpigagliaF.BarbantiP.Mastrantonio (2008b) Tetracycline resistance gene tet(W) in the pathogenic bacterium Clostridium difficile. Antimicrob Agents Chemother52: 770–773.
142. P.SpigagliaF.BarbantiT.LouieF.BarbutP.Mastrantonio (2009) Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. Antimicrob Agents Chemother53: 2463–2468.
143. P.SpigagliaF.BarbantiA.DionisiP.Mastrantonio (2010) Clostridium difficile isolates resistant to fluoroquinolones in Italy: emergence of PCR ribotype 018. J Clin Microbiol48: 2892–2896.
144. P.SpigagliaF.BarbantiP.Mastrantoniofor the European Study Group on Clostridium difficile (ESGCD) (2011) Multidrug resistance in European Clostridium difficile clinical isolates. J Antimicrob Chemother66: 2227–2234.
145. Spigaglia, P., Barbanti, F., Morandi, M., Moro, M. and Mastrantonio, P. (2015) Diagnostic testing for Clostridium difficile in Italian microbiological laboratories. Anaerobe, in press. DOI: 10.1016/j.anaerobe.2015.11.002
146. P.SpigagliaV.CarucciF.BarbantiP.Mastrantonio (2005) ErmB determinants and Tn916-like elements in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother49: 2550–2553.
147. P.SpigagliaI.DrigoF.BarbantiP.MastrantonioL.BanoC.Bacchin (2015) Antibiotic resistance patterns and PCR-ribotyping of Clostridium difficile strains isolated from swine and dogs in Italy. Anaerobe31: 42–46.
148. P.SpigagliaP.Mastrantonio (2004) Comparative analysis of Clostridium difficile clinical isolates belonging to different genetic lineages and time periods. J Med Microbiol53: 1129–1136.
149. A.SrivastavaM.TalaueS.LiuD.DegenR.EbrightE.Sineva (2011) New target for inhibition of bacterial RNA polymerase: “switch region”. Curr Opin Microbiol Antimicrob Genom14: 532–543.
150. G.TannockK.MunroC.TaylorB.LawleyW.YoungB.Byrne (2010) A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology156: 3354–3359.
151. F.TenoverI.TicklerD.Persing (2012) Antimicrobial-resistant strains of Clostridium difficile from North America. Antimicrob Agents Chemother56: 2929–2932.
152. G.TerhesA.MaruyamaK.LatkóczyL.SzikraM.Konkoly-ThegeG.Princz (2014) In vitro antibiotic susceptibility profile of Clostridium difficile excluding PCR ribotype 027 outbreak strain in Hungary. Anaerobe30: 41–44.
153. K.ToL.Napolitano (2014) Clostridium difficile infection: update on diagnosis, epidemiology, and treatment strategies. Surg Infect15: 490–502.
154. E.ValienteL.DawsonM.CairnsR.StablerB.Wren (2012) Emergence of new PCR ribotypes from the hypervirulent Clostridium difficile 027 lineage. J Med Microbiol61: 49–56.
155. K.VardakasK.PolyzosK.PatouniP.RafailidisG.SamonisM.Falagas (2012) Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. Int J Antimicrob Agents40: 1–8.
156. J.VarshneyK.VeryJ.WilliamsJ.HegartyD.StewartJ.Lumadue (2014) Characterization of Clostridium difficile isolates from human fecal samples and retail meat from Pennsylvania. Foodborne Pathog Dis11: 822–829.
157. Vuotto, C., Moura, I., Barbanti, F., Donelli, G., Spigaglia, P. (2015) Sub-inhibitory concentrations of metronidazole increase biofilm formation in Clostridium difficile strains. Pathog Dis, in press. DOI: 10.1093/femspd/ftv114
158. A.WalktyD.BoydD.GravelJ.HutchinsonA.McGeerD.Moore (2010) Molecular characterization of moxifloxacin resistance from Canadian Clostridium difficile clinical isolates. Diagn Microbiol Infect Dis66: 419–424.
159. H.WangM.SmithP.Mullany (2006) The conjugative transposon Tn5397 has a strong preference for integration into its Clostridium difficile target site. J Bacteriol188: 4871–4878.
160. F.WaselsP.SpigagliaF.BarbantiP.Mastrantonio (2013) Clostridium difficile erm(B)-containing elements and the burden on the in vitro fitness. J Med Microbiol62: 1461–1467.
161. F.WaselsM.MonotP.SpigagliaF.BarbantiL.MaC.Bouchier (2014) Inter- and intraspecies transfer of a Clostridium difficile conjugative transposon conferring resistance to MLSB. Microb Drug Resist20: 555–560.
162. F.WaselsS.KuehneS.CartmanP.SpigagliaF.BarbantiN.Minton (2015a) Fluoroquinolone resistance does not impose a cost on the fitness of Clostridium difficile in vitro. Antimicrob Agents Chemother59: 1794–1796.
163. F.WaselsP.SpigagliaF.BarbantiM.MonotL.VillaB.Dupuy (2015b) Integration of erm(B)-containing elements through large chromosome fragment exchange in Clostridium difficile. Mob Genet Elements1: 12–16.
164. I.WeberE.RieraC.DénizJ.PérezA.OliverA.Mena (2013) Molecular epidemiology and resistance profiles of Clostridium difficile in a tertiary care hospital in Spain. Int J Med Microbiol303: 128–133.
165. K.WetterwikG.Trowald-WighL.FernströmK.Krovacek (2013) Clostridium difficile in faeces from healthy dogs and dogs with diarrhea. Acta Vet Scand55: 23.
166. J.WiströmS.NorrbyE.MyhreS.ErikssonG.GranströmL.Lagergren (2001) Frequency of antibiotic-associated diarrhea in 2462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother47: 43–50.
167. B.WrenP.MullanyC.ClaytonS.Tabaqchali (1988) Molecular cloning and genetic analysis of a chloramphenicol acetyltransferase determinant from Clostridium difficile. Antimicrob Agents Chemother32: 1213–1217.
168. B.WrenP.MullanyC.ClaytonS.Tabaqchali (1989) Nucleotide sequence of a chloramphenicol acetyl transferase gene from Clostridium difficile. Nucleic Acids Res17: 4877.
169. G.YoungP.WardN.BayleyD.GordonG.HigginsJ.Trapani (1985) Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. Gastroenterology89: 1038–1045.
170. X.YuD.Sun (2013) Macrocyclic drugs and synthetic methodologies toward macrocycles. Molecules18: 6230–6268.
171. Y.ZhouC.BurnhamT.HinkL.ChenN.ShaikhA.Wollam (2014) Phenotypic and genotypic analysis of Clostridium difficile isolates: a single-center study. J Clin Microbiol52: 4260–4266.